Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.
about
Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approachesOptimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?Deletion of antigens of the Lewis a/b blood group family in human prostatic carcinomaHuman antibodies for immunotherapy development generated via a human B cell hybridoma technology.Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in miceHuman IgM antibody therapy for HIV-1 infection.Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.Possibilities for active immunotherapy of human cancer.Glioma heterogeneity in vitro: the significance of growth factors and gangliosides.Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrowCellular immuno-PCR. Detection of a carbohydrate tumor marker.Tumor-Associated Glycans and Immune SurveillanceSynergism between membrane gangliosides and Arg-Gly-Asp-directed glycoprotein receptors in attachment to matrix proteins by melanoma cellsRole of monoclonal antibodies in tumor-specific immunity.Role of gangliosides in active immunotherapy with melanoma vaccine.Glycans as targets for therapeutic antitumor antibodies.Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies.Intralesional therapy for metastatic melanoma.Genetically engineered antibody molecules: new tools for cancer therapy.Immunotherapy of melanoma: current status and prospects for the future.Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer.Gangliosides in human uveal melanoma metastatic process.A cancer-reactive human monoclonal antibody derived from a colonic cancer patient treated with local immunotherapy.Update on active specific immunotherapy with melanoma vaccines.In vitro anti-tumor activity of anti-c-erbB-2 x anti-CD3 epsilon bifunctional monoclonal antibody.Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale.A human glioma cell line retaining expression of GFAP and gangliosides, recognized by A2B5 and LB1 antibodies, after prolonged passage.An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.Re-inventing intratumoral immunotherapy for melanoma.Clinical trials with VMO for melanoma.Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma.Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.A human monoclonal antibody recognizing a surface antigen on stomach cancer cells.Expression of mouse sialic acid on gangliosides of a human glioma grown as a xenograft in SCID mice.
P2860
Q21129299-B0565B80-3ABE-4D08-A94F-309CCE68E80AQ24803763-49EF6B95-CD76-4C00-BC44-92785A814CC3Q30444972-C13E2D68-B776-4917-A466-12A1563A516FQ33234976-E37313EA-181B-4387-B531-2D14270D23DBQ33312280-A15C155B-BFF1-4233-B2C2-185FE8A65753Q33753260-5C8614DD-8DEF-4724-AC96-4B069CBAED6DQ34389202-9B4EE757-B768-4A8F-B8D4-504F6485DEDCQ34625006-385A67F3-620E-487C-952A-65242FC430A9Q35326752-80E848AE-F38C-4A1E-B970-DF3C28350D5EQ35555396-82E8C49A-F442-4AEB-886E-94E0BDC6D209Q35747067-52D26CAA-7E3D-47D8-BFE1-1C9C589D6C37Q35765166-F1929E0D-175E-4AC6-99B4-1484899B97DDQ35890610-51DF53BC-2A1E-417C-B0DA-02D3E54CF98AQ36219616-9B21DBFA-7328-4903-BE49-CC65C08B4D64Q36739762-FD4833A9-6948-4CB5-8B5C-BC7BD6B81DB3Q36930077-006C1FDA-65DB-4C09-8161-F9C7508FD585Q38034815-98D1317A-4BB3-4F63-8806-21A54D3126A4Q38195895-C45801A2-1C8F-4432-8646-DE9E2D2DF705Q38266193-C2A8F81D-661F-4114-AFC5-845D88BCBC73Q39644773-E4452BA2-F191-4BC6-A255-5F2BCE6BF744Q40899717-7F981867-41D8-45E8-B40F-57D61BB34F0BQ41014965-2AEE77D9-A957-49C3-B21F-A87F73D98D4DQ41165987-3B09CD98-8D0E-4B66-A284-617A3EFA9EB1Q41580452-F8039151-9BD2-4A3E-94B7-70D6CEFD2AE8Q41589321-96C5B636-009F-4E61-BE90-032968933E25Q41622446-6F097BC2-7C0D-4C40-8B49-FE9009B55DDAQ41629044-E1A703B5-127B-4DD0-883D-4EE21690A807Q41713360-C5C5C4AE-8295-4C49-9541-2D7ECF705422Q44083589-725ADD5B-4469-4B6B-BD87-38F7D12FFD56Q44607083-1DB00F02-6980-4B91-BF03-697AECF49502Q44772535-124D9DA8-4B75-4EEF-9F37-E9B6AFA27A24Q45997022-5FFE723C-4E07-46DF-92D0-E3C70E81DE24Q48615588-DD8AA493-DA5B-4424-8945-1E7387394D2CQ55317230-0E9BB5F8-F19C-4619-B301-868FEE9AAF1AQ55476853-E7B86B68-079A-4F16-9829-80B1A308E4BB
P2860
Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Regression of cutaneous metast ...... l antibody to ganglioside GD2.
@en
Regression of cutaneous metast ...... l antibody to ganglioside GD2.
@nl
type
label
Regression of cutaneous metast ...... l antibody to ganglioside GD2.
@en
Regression of cutaneous metast ...... l antibody to ganglioside GD2.
@nl
prefLabel
Regression of cutaneous metast ...... l antibody to ganglioside GD2.
@en
Regression of cutaneous metast ...... l antibody to ganglioside GD2.
@nl
P2860
P356
P1476
Regression of cutaneous metast ...... l antibody to ganglioside GD2.
@en
P2093
P2860
P304
P356
10.1073/PNAS.83.22.8694
P407
P577
1986-11-01T00:00:00Z